Closed Loop Medicine Secures Additional Key GLP-1 Patent for Its AI-Based Dosing Platform: Powering Personalized, Direct-to-Patient Therapies

Closed Loop Medicine (CLM) announced the allowance of a key U.S. patent (Application No. 18/734,284), covering personalized and adaptive dosing of GLP-1 therapies, strengthening its AI-based, patient-specific treatment platform1.

The patent offers broad protection for CLM’s method of calculating and optimizing semaglutide and other incretin doses based on individual patient data such as current and target weight. Advanced claims include machine learning and pharmacokinetic modeling to further refine dosing and enable real-time titration1.

A closed-loop feedback system is enabled, whereby patient progress data continuously feeds back into the platform, providing automatic, highly personalized dose recommendations that adapt over time1.

While the specific claims focus on semaglutide, the patent supports the general concept of individually tailored dosing for all GLP-1 drugs, and CLM is pursuing additional patents for broader incretin coverage1.

CLM launched 'WeDosify' in September, a GLP-1 dosing tool that represents the first commercial application of this patented technology in real-world clinical and direct-to-patient use14.

CLM’s incretin portfolio now includes three granted or allowed patent families, with three more pending and further continuations planned. Their IP also covers software platform innovations and other drug therapy areas1.

WeDosify, informed by large-scale clinical data, supports clinicians in optimizing GLP-1 titration, aiming to reduce side effects and improve adherence to treatment. It leverages data-driven, real-time updates for user-specific recommendations4.

The global anti-obesity market, where GLP-1 drugs play a key role, is rapidly growing, yet discontinuation rates are high due to dose-related side effects and lack of personalized support—challenges CLM's solutions aim to address4.

Sources:

1. https://www.closedloopmedicine.com/closed-loop-medicine-secures-additional-key-glp-1-patent-for-its-ai-based-dosing-platform-powering-personalized-direct-to-patient-therapies/

4. https://www.businesswire.com/news/home/20250918277983/en/Closed-Loop-Medicine-Launches-First-Personalized-GLP-1-Dosing-Platform-in-U.S.